Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
Go back to Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma| (NASDAQ: NVCT) | Delayed: 20.70 +0.11 (0.53%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $20.59 | 52 Week High | $ | |||
| Open | $20.63 | 52 Week Low | $ | |||
| Day High | $21.72 | P/E | N/A | |||
| Day Low | $19.94 | EPS | $ | |||
| Volume | 203,582 | |||||



